Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSB0777
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Unknown
01
Overview
PSB0777 is a potent, selective small molecule full agonist of the adenosine A2A receptor (Ki ≈ 44 nM for rat A2A), exhibiting strong selectivity over other adenosine receptor subtypes. It is investigated as a neuroprotective and antiplatelet agent, with mechanisms impacting synaptic function, neurotransmission, and platelet aggregation. PSB0777 has shown preclinical efficacy for modulating synaptic proteins and AMPA receptors, highlighting its therapeutic relevance for neuropsychiatric and neurodegenerative disorders, as well as for cardiovascular/antiplatelet applications[1][3][4][5][8].
- Other names
- PSB 0777PSB0777PSB-0777PSB-0777 ammonium saltPSB0777 ammonium saltPSB 0777 ammonium salt
02
Targets
ADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on PSB0777.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSB0777.